Purpose-driven investment support
We offer clients trusted advice and proven expertise, and work to create a lasting social impact with our business
About us
Atain & Company is an independent advisory firm specializing in investment due diligence and value creation for innovative and growth-oriented companies.
We work with a variety of clients, from financial investors looking to acquire and grow businesses, donors seeking to strengthen private sector to entrepreneurs and corporates tackling strategic issues. We help to source deals and conduct due diligence to formulate investment decisions. Post-deal, we build strategies to power a company’s growth, resilience, efficiency, and competitiveness.
As investors ourselves, we are committed to having a sustainable impact and helping clients embed ESG in value creation to achieve lasting profitability and tangible social benefits
Our focus on life sciences
Health Care
We focus on manufacturers of innovative and generic medicines, providers of pharmaceutical services and health care IT solutions
Private Equity
We partner with private equity groups and financial investors to identify unique investment opportunities with strong market fundamentals.
Industrial biotechnology
We provide commercial and strategic support to investors and businesses in the industrial and agricultural sectors of biomanufacturing and bioeconomy
Our services
Since our founding in 2020, we've witnessed massive disruptions in capital and healthcare markets. It transformed how companies operate and utilize their assets for financial and strategic advantage.
We help clients embrace new opportunities to create more value for their stakeholders and build a more prosperous and resilient future
MORE OF OUR WORK
Our capabilities
Maximising the ESG Impact >
We aim to be a partner and advisor on ESG topics to drive economic growth that advances sustainability, resilience, and social inclusion. Learn how we help clients embed ESG considerations into their strategies to achieve clear differentiation and seize leadership opportunities
Latest news
We're proud to support our clients journey in building capabilities across their organizations, creating impact that extends beyond financial and operational success. Here’s a glimpse into that journey.
Private EquityWhat headwinds and tailwinds are impacting fundraising, deal activity, value creation, and investment performance in private markets in 2024 and the year ahead
Insights • January 2025
ExplorePrivate markets health check: rebounding with strength in 2025
Medical devicesLearn how our due diligence services have helped clients across a wide range of products and geographies find quality, reliable, and financially viable manufacturers
Case study • August 2024
ExploreOperational and legal due diligence on manufacturers of medical products
BiopharmaceuticalsThe global pharma engaged us to assess how the company could interact with payers and payer advisory stakeholders to advance the field prior to launch
Case study • March, 2024
ExploreEngaging payers in rare disease to prepare the market for gene therapy
Seed InvestmentsWhat challenges and opportunities are shaping Ukraine’s innovation landscape, and how can EU accession drive deeper technological advancements?
Report • August 2024
ExploreTracing the origins of new ventures in intellectual property landscape
“We advise and invest in companies that generate returns and create a positive impact on health, nature, and society.”
— Dr. Tetiana Kosten
Tetiana Kosten is the founder and director of Atain. She established the consultancy in 2020, supporting investors through the fast-paced post-pandemic investment surge.
Tetiana has 10 years of professional consulting experience specialising in investment due diligence and strategy. She developed a strong interest in healthcare investments while working at Roland Berger in Munich. Her team’s approach to due diligence incorporates proprietary knowledge and deep expertise of the life sciences ecosystem, addressing investors’ requirements for both mature and early-stage companies.
Tetiana holds an MSc in Biotechnology from Shevchenko University in Kyiv and a PhD from the Max Delbrück Center and Free University in Berlin. She speaks English, and German and is committed to promoting women’s entrepreneurship.
Our investment principles
We consider equity and quasi-equity majority and co-investments in mid-stage venture and growth-stage unlisted companies. Our focus is on the full spectrum of the bioeconomy and life sciences, supporting companies and projects across the health, industrial, and agricultural sectors in Europe. We take an active, hands-on approach to help our portfolio grow and deliver long-term value
Values driven
Highest professional standards
Passion for performance
Compassionate leadership
Leading by example
Ambitious strategy
Life Sciences focus
Return driven
Long-term outlook
Impact beyond profit
Excellence in operations
Governance and processes
Ensuring solid foundations for success
Strong collaboration and alignment
Accountability and transparency
Join our network
We are proud to have built a network of thousands of industry experts who have held senior roles in private equity, venture capital, management, or the industry, and we are excited to bring their valuable expertise to our deals and projects. Are you interested in joining our team? Contact us!